Contribute Try STAT+ Today

People often ask me how I select the nominees for best biopharma CEO of the year — an honorific that I’ve been giving out since 2008. The winnowing process starts with public companies — private company CEOs are not considered. (Sorry, startup CEOs, you need to grow up first.) Delivering significant value to shareholders is very important. Beyond that, the process gets more subjective. There’s no algorithm, spreadsheet, or fancy analysis that spits out definitive answers. I solicit potential nominees via social media and ask some trusted sources for advice, but the final list relies a lot on my gut and experience. A big jump in stock price is nice, but how was the outperformance delivered and why? Is there a compelling story behind the achievement?

This year’s best biopharma CEO finalists — four in total — come from a list of just over two dozen names. Congratulations to them all. There were two or three worthy candidates who were close but didn’t quite make the cut. Apologies, but perhaps next year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.